A combination of menin inhibitor SNDX-50469 and CDK6 inhibitor abemaciclib has a synergistic activity in non-AMKL cell lines (MOLM13 and MV4-11) and patient-derived AML blasts harboring KMT2Ar (Fiskus et al., 2022). Here, MEN1 is linked to acute myeloid leukemia.